Watchdog set to reject four drugs for kidney cancer on the NHSBMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a1262 (Published 14 August 2008) Cite this as: BMJ 2008;337:a1262
- Adrian O’Dowd
The UK clinical watchdog has proposed rejecting four drugs for use on the NHS for advanced renal cancer, saying they are clinically effective but not good value for money.
The National Institute for Health and Clinical Excellence (NICE) issued draft guidance this week that rejects the drugs sunitinib (Sutent), bevacizumab (Avastin), sorafenib (Nexavar), and temsirolimus (Torisel). The guidance is out for consultation until 29 August, with the final guidance due in early 2009.
The recommendation, which applies in England, Wales, and Northern Ireland, has provoked an angry response from charities that claimed that NICE’s appraisal system was not appropriate for all types of drugs.
NICE’s draft guidance says that it does not recommend these drugs for advanced or metastatic …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial